Global Selective PDE Inhibitors Market Research Report 2025

1 Selective PDE Inhibitors Market Overview
1.1 Product Definition
1.2 Selective PDE Inhibitors by Type
1.2.1 Global Selective PDE Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 PDE-3
1.2.3 PDE-4
1.2.4 PDE-5
1.3 Selective PDE Inhibitors by Application
1.3.1 Global Selective PDE Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Heart And Circulatory Conditions
1.3.3 Inflammatory Diseases
1.3.4 Reproductive (Male) Disorders
1.3.5 Respiratory Conditions
1.3.6 Others
1.4 Global Selective PDE Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Selective PDE Inhibitors Revenue 2020-2031
1.4.2 Global Selective PDE Inhibitors Sales 2020-2031
1.4.3 Global Selective PDE Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Selective PDE Inhibitors Market Competition by Manufacturers
2.1 Global Selective PDE Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global Selective PDE Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Selective PDE Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Selective PDE Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Selective PDE Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Selective PDE Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of Selective PDE Inhibitors, Date of Enter into This Industry
2.8 Global Selective PDE Inhibitors Market Competitive Situation and Trends
2.8.1 Global Selective PDE Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Selective PDE Inhibitors Players Market Share by Revenue
2.8.3 Global Selective PDE Inhibitors Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Selective PDE Inhibitors Market Scenario by Region
3.1 Global Selective PDE Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Selective PDE Inhibitors Sales by Region: 2020-2031
3.2.1 Global Selective PDE Inhibitors Sales by Region: 2020-2025
3.2.2 Global Selective PDE Inhibitors Sales by Region: 2026-2031
3.3 Global Selective PDE Inhibitors Revenue by Region: 2020-2031
3.3.1 Global Selective PDE Inhibitors Revenue by Region: 2020-2025
3.3.2 Global Selective PDE Inhibitors Revenue by Region: 2026-2031
3.4 North America Selective PDE Inhibitors Market Facts & Figures by Country
3.4.1 North America Selective PDE Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Selective PDE Inhibitors Sales by Country (2020-2031)
3.4.3 North America Selective PDE Inhibitors Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Selective PDE Inhibitors Market Facts & Figures by Country
3.5.1 Europe Selective PDE Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Selective PDE Inhibitors Sales by Country (2020-2031)
3.5.3 Europe Selective PDE Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Selective PDE Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Selective PDE Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Selective PDE Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific Selective PDE Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Selective PDE Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Selective PDE Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Selective PDE Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America Selective PDE Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Selective PDE Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Selective PDE Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Selective PDE Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa Selective PDE Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Selective PDE Inhibitors Sales by Type (2020-2031)
4.1.1 Global Selective PDE Inhibitors Sales by Type (2020-2025)
4.1.2 Global Selective PDE Inhibitors Sales by Type (2026-2031)
4.1.3 Global Selective PDE Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global Selective PDE Inhibitors Revenue by Type (2020-2031)
4.2.1 Global Selective PDE Inhibitors Revenue by Type (2020-2025)
4.2.2 Global Selective PDE Inhibitors Revenue by Type (2026-2031)
4.2.3 Global Selective PDE Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global Selective PDE Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global Selective PDE Inhibitors Sales by Application (2020-2031)
5.1.1 Global Selective PDE Inhibitors Sales by Application (2020-2025)
5.1.2 Global Selective PDE Inhibitors Sales by Application (2026-2031)
5.1.3 Global Selective PDE Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global Selective PDE Inhibitors Revenue by Application (2020-2031)
5.2.1 Global Selective PDE Inhibitors Revenue by Application (2020-2025)
5.2.2 Global Selective PDE Inhibitors Revenue by Application (2026-2031)
5.2.3 Global Selective PDE Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global Selective PDE Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Company Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Eli Lilly Selective PDE Inhibitors Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bayer Selective PDE Inhibitors Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Hikma Pharmaceuticals
6.3.1 Hikma Pharmaceuticals Company Information
6.3.2 Hikma Pharmaceuticals Description and Business Overview
6.3.3 Hikma Pharmaceuticals Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Hikma Pharmaceuticals Selective PDE Inhibitors Product Portfolio
6.3.5 Hikma Pharmaceuticals Recent Developments/Updates
6.4 Takeda Pharmaceutical
6.4.1 Takeda Pharmaceutical Company Information
6.4.2 Takeda Pharmaceutical Description and Business Overview
6.4.3 Takeda Pharmaceutical Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Takeda Pharmaceutical Selective PDE Inhibitors Product Portfolio
6.4.5 Takeda Pharmaceutical Recent Developments/Updates
6.5 Teva Pharmaceutical
6.5.1 Teva Pharmaceutical Company Information
6.5.2 Teva Pharmaceutical Description and Business Overview
6.5.3 Teva Pharmaceutical Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Teva Pharmaceutical Selective PDE Inhibitors Product Portfolio
6.5.5 Teva Pharmaceutical Recent Developments/Updates
6.6 Torrent Pharmaceuticals
6.6.1 Torrent Pharmaceuticals Company Information
6.6.2 Torrent Pharmaceuticals Description and Business Overview
6.6.3 Torrent Pharmaceuticals Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Torrent Pharmaceuticals Selective PDE Inhibitors Product Portfolio
6.6.5 Torrent Pharmaceuticals Recent Developments/Updates
6.7 Viatris
6.7.1 Viatris Company Information
6.7.2 Viatris Description and Business Overview
6.7.3 Viatris Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Viatris Selective PDE Inhibitors Product Portfolio
6.7.5 Viatris Recent Developments/Updates
6.8 Otsuka Pharmaceutical
6.8.1 Otsuka Pharmaceutical Company Information
6.8.2 Otsuka Pharmaceutical Description and Business Overview
6.8.3 Otsuka Pharmaceutical Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Otsuka Pharmaceutical Selective PDE Inhibitors Product Portfolio
6.8.5 Otsuka Pharmaceutical Recent Developments/Updates
6.9 Sawai Pharmaceutical
6.9.1 Sawai Pharmaceutical Company Information
6.9.2 Sawai Pharmaceutical Description and Business Overview
6.9.3 Sawai Pharmaceutical Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Sawai Pharmaceutical Selective PDE Inhibitors Product Portfolio
6.9.5 Sawai Pharmaceutical Recent Developments/Updates
6.10 Eurofarma
6.10.1 Eurofarma Company Information
6.10.2 Eurofarma Description and Business Overview
6.10.3 Eurofarma Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Eurofarma Selective PDE Inhibitors Product Portfolio
6.10.5 Eurofarma Recent Developments/Updates
6.11 Italfarmaco
6.11.1 Italfarmaco Company Information
6.11.2 Italfarmaco Description and Business Overview
6.11.3 Italfarmaco Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Italfarmaco Selective PDE Inhibitors Product Portfolio
6.11.5 Italfarmaco Recent Developments/Updates
6.12 Korea United Pharm
6.12.1 Korea United Pharm Company Information
6.12.2 Korea United Pharm Description and Business Overview
6.12.3 Korea United Pharm Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Korea United Pharm Selective PDE Inhibitors Product Portfolio
6.12.5 Korea United Pharm Recent Developments/Updates
6.13 The Menarini Group
6.13.1 The Menarini Group Company Information
6.13.2 The Menarini Group Description and Business Overview
6.13.3 The Menarini Group Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 The Menarini Group Selective PDE Inhibitors Product Portfolio
6.13.5 The Menarini Group Recent Developments/Updates
6.14 Pfizer
6.14.1 Pfizer Company Information
6.14.2 Pfizer Description and Business Overview
6.14.3 Pfizer Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Pfizer Selective PDE Inhibitors Product Portfolio
6.14.5 Pfizer Recent Developments/Updates
6.15 Sanofi
6.15.1 Sanofi Company Information
6.15.2 Sanofi Description and Business Overview
6.15.3 Sanofi Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Sanofi Selective PDE Inhibitors Product Portfolio
6.15.5 Sanofi Recent Developments/Updates
6.16 Amgen
6.16.1 Amgen Company Information
6.16.2 Amgen Description and Business Overview
6.16.3 Amgen Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Amgen Selective PDE Inhibitors Product Portfolio
6.16.5 Amgen Recent Developments/Updates
6.17 AstraZeneca
6.17.1 AstraZeneca Company Information
6.17.2 AstraZeneca Description and Business Overview
6.17.3 AstraZeneca Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.17.4 AstraZeneca Selective PDE Inhibitors Product Portfolio
6.17.5 AstraZeneca Recent Developments/Updates
6.18 Anacor Pharmaceuticals
6.18.1 Anacor Pharmaceuticals Company Information
6.18.2 Anacor Pharmaceuticals Description and Business Overview
6.18.3 Anacor Pharmaceuticals Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Anacor Pharmaceuticals Selective PDE Inhibitors Product Portfolio
6.18.5 Anacor Pharmaceuticals Recent Developments/Updates
6.19 Glenmark Pharmaceuticals
6.19.1 Glenmark Pharmaceuticals Company Information
6.19.2 Glenmark Pharmaceuticals Description and Business Overview
6.19.3 Glenmark Pharmaceuticals Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Glenmark Pharmaceuticals Selective PDE Inhibitors Product Portfolio
6.19.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.20 Bristol Myers Squibb
6.20.1 Bristol Myers Squibb Company Information
6.20.2 Bristol Myers Squibb Description and Business Overview
6.20.3 Bristol Myers Squibb Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Bristol Myers Squibb Selective PDE Inhibitors Product Portfolio
6.20.5 Bristol Myers Squibb Recent Developments/Updates
6.21 OriFarm
6.21.1 OriFarm Company Information
6.21.2 OriFarm Description and Business Overview
6.21.3 OriFarm Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.21.4 OriFarm Selective PDE Inhibitors Product Portfolio
6.21.5 OriFarm Recent Developments/Updates
6.22 Kohl Medical
6.22.1 Kohl Medical Company Information
6.22.2 Kohl Medical Description and Business Overview
6.22.3 Kohl Medical Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Kohl Medical Selective PDE Inhibitors Product Portfolio
6.22.5 Kohl Medical Recent Developments/Updates
6.23 Paranova
6.23.1 Paranova Company Information
6.23.2 Paranova Description and Business Overview
6.23.3 Paranova Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Paranova Selective PDE Inhibitors Product Portfolio
6.23.5 Paranova Recent Developments/Updates
6.24 Arcutis Biotherapeutics
6.24.1 Arcutis Biotherapeutics Company Information
6.24.2 Arcutis Biotherapeutics Description and Business Overview
6.24.3 Arcutis Biotherapeutics Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Arcutis Biotherapeutics Selective PDE Inhibitors Product Portfolio
6.24.5 Arcutis Biotherapeutics Recent Developments/Updates
6.25 MSN Laboratories
6.25.1 MSN Laboratories Company Information
6.25.2 MSN Laboratories Description and Business Overview
6.25.3 MSN Laboratories Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.25.4 MSN Laboratories Selective PDE Inhibitors Product Portfolio
6.25.5 MSN Laboratories Recent Developments/Updates
6.26 Hypera Pharma
6.26.1 Hypera Pharma Company Information
6.26.2 Hypera Pharma Description and Business Overview
6.26.3 Hypera Pharma Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.26.4 Hypera Pharma Selective PDE Inhibitors Product Portfolio
6.26.5 Hypera Pharma Recent Developments/Updates
6.27 CSPC Ouyi Pharmaceutical
6.27.1 CSPC Ouyi Pharmaceutical Company Information
6.27.2 CSPC Ouyi Pharmaceutical Description and Business Overview
6.27.3 CSPC Ouyi Pharmaceutical Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.27.4 CSPC Ouyi Pharmaceutical Selective PDE Inhibitors Product Portfolio
6.27.5 CSPC Ouyi Pharmaceutical Recent Developments/Updates
6.28 Qilu Pharmaceutical
6.28.1 Qilu Pharmaceutical Company Information
6.28.2 Qilu Pharmaceutical Description and Business Overview
6.28.3 Qilu Pharmaceutical Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.28.4 Qilu Pharmaceutical Selective PDE Inhibitors Product Portfolio
6.28.5 Qilu Pharmaceutical Recent Developments/Updates
6.29 Yabao Pharmaceuticals
6.29.1 Yabao Pharmaceuticals Company Information
6.29.2 Yabao Pharmaceuticals Description and Business Overview
6.29.3 Yabao Pharmaceuticals Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.29.4 Yabao Pharmaceuticals Selective PDE Inhibitors Product Portfolio
6.29.5 Yabao Pharmaceuticals Recent Developments/Updates
6.30 Lunan Better Pharmaceutical
6.30.1 Lunan Better Pharmaceutical Company Information
6.30.2 Lunan Better Pharmaceutical Description and Business Overview
6.30.3 Lunan Better Pharmaceutical Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.30.4 Lunan Better Pharmaceutical Selective PDE Inhibitors Product Portfolio
6.30.5 Lunan Better Pharmaceutical Recent Developments/Updates
6.31 Yangtze River Pharmaceuticals
6.31.1 Yangtze River Pharmaceuticals Company Information
6.31.2 Yangtze River Pharmaceuticals Description and Business Overview
6.31.3 Yangtze River Pharmaceuticals Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.31.4 Yangtze River Pharmaceuticals Selective PDE Inhibitors Product Portfolio
6.31.5 Yangtze River Pharmaceuticals Recent Developments/Updates
6.32 Guangzhou Baiyunshan
6.32.1 Guangzhou Baiyunshan Company Information
6.32.2 Guangzhou Baiyunshan Description and Business Overview
6.32.3 Guangzhou Baiyunshan Selective PDE Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.32.4 Guangzhou Baiyunshan Selective PDE Inhibitors Product Portfolio
6.32.5 Guangzhou Baiyunshan Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Selective PDE Inhibitors Industry Chain Analysis
7.2 Selective PDE Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Selective PDE Inhibitors Production Mode & Process Analysis
7.4 Selective PDE Inhibitors Sales and Marketing
7.4.1 Selective PDE Inhibitors Sales Channels
7.4.2 Selective PDE Inhibitors Distributors
7.5 Selective PDE Inhibitors Customer Analysis
8 Selective PDE Inhibitors Market Dynamics
8.1 Selective PDE Inhibitors Industry Trends
8.2 Selective PDE Inhibitors Market Drivers
8.3 Selective PDE Inhibitors Market Challenges
8.4 Selective PDE Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Selective PDE Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Selective PDE Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Selective PDE Inhibitors Market Competitive Situation by Manufacturers in 2024
Table 4. Global Selective PDE Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Selective PDE Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Selective PDE Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Selective PDE Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Selective PDE Inhibitors Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Selective PDE Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Selective PDE Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Selective PDE Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of Selective PDE Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Selective PDE Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Selective PDE Inhibitors as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Selective PDE Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Selective PDE Inhibitors Sales by Region (2020-2025) & (K Units)
Table 18. Global Selective PDE Inhibitors Sales Market Share by Region (2020-2025)
Table 19. Global Selective PDE Inhibitors Sales by Region (2026-2031) & (K Units)
Table 20. Global Selective PDE Inhibitors Sales Market Share by Region (2026-2031)
Table 21. Global Selective PDE Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Selective PDE Inhibitors Revenue Market Share by Region (2020-2025)
Table 23. Global Selective PDE Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Selective PDE Inhibitors Revenue Market Share by Region (2026-2031)
Table 25. North America Selective PDE Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Selective PDE Inhibitors Sales by Country (2020-2025) & (K Units)
Table 27. North America Selective PDE Inhibitors Sales by Country (2026-2031) & (K Units)
Table 28. North America Selective PDE Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Selective PDE Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Selective PDE Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Selective PDE Inhibitors Sales by Country (2020-2025) & (K Units)
Table 32. Europe Selective PDE Inhibitors Sales by Country (2026-2031) & (K Units)
Table 33. Europe Selective PDE Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Selective PDE Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Selective PDE Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Selective PDE Inhibitors Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Selective PDE Inhibitors Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Selective PDE Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Selective PDE Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Selective PDE Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Selective PDE Inhibitors Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Selective PDE Inhibitors Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Selective PDE Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Selective PDE Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Selective PDE Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Selective PDE Inhibitors Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Selective PDE Inhibitors Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Selective PDE Inhibitors Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Selective PDE Inhibitors Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Selective PDE Inhibitors Sales (K Units) by Type (2020-2025)
Table 51. Global Selective PDE Inhibitors Sales (K Units) by Type (2026-2031)
Table 52. Global Selective PDE Inhibitors Sales Market Share by Type (2020-2025)
Table 53. Global Selective PDE Inhibitors Sales Market Share by Type (2026-2031)
Table 54. Global Selective PDE Inhibitors Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Selective PDE Inhibitors Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Selective PDE Inhibitors Revenue Market Share by Type (2020-2025)
Table 57. Global Selective PDE Inhibitors Revenue Market Share by Type (2026-2031)
Table 58. Global Selective PDE Inhibitors Price (US$/Unit) by Type (2020-2025)
Table 59. Global Selective PDE Inhibitors Price (US$/Unit) by Type (2026-2031)
Table 60. Global Selective PDE Inhibitors Sales (K Units) by Application (2020-2025)
Table 61. Global Selective PDE Inhibitors Sales (K Units) by Application (2026-2031)
Table 62. Global Selective PDE Inhibitors Sales Market Share by Application (2020-2025)
Table 63. Global Selective PDE Inhibitors Sales Market Share by Application (2026-2031)
Table 64. Global Selective PDE Inhibitors Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Selective PDE Inhibitors Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Selective PDE Inhibitors Revenue Market Share by Application (2020-2025)
Table 67. Global Selective PDE Inhibitors Revenue Market Share by Application (2026-2031)
Table 68. Global Selective PDE Inhibitors Price (US$/Unit) by Application (2020-2025)
Table 69. Global Selective PDE Inhibitors Price (US$/Unit) by Application (2026-2031)
Table 70. Eli Lilly Company Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Eli Lilly Selective PDE Inhibitors Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. Bayer Company Information
Table 76. Bayer Description and Business Overview
Table 77. Bayer Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Bayer Selective PDE Inhibitors Product
Table 79. Bayer Recent Developments/Updates
Table 80. Hikma Pharmaceuticals Company Information
Table 81. Hikma Pharmaceuticals Description and Business Overview
Table 82. Hikma Pharmaceuticals Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Hikma Pharmaceuticals Selective PDE Inhibitors Product
Table 84. Hikma Pharmaceuticals Recent Developments/Updates
Table 85. Takeda Pharmaceutical Company Information
Table 86. Takeda Pharmaceutical Description and Business Overview
Table 87. Takeda Pharmaceutical Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Takeda Pharmaceutical Selective PDE Inhibitors Product
Table 89. Takeda Pharmaceutical Recent Developments/Updates
Table 90. Teva Pharmaceutical Company Information
Table 91. Teva Pharmaceutical Description and Business Overview
Table 92. Teva Pharmaceutical Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Teva Pharmaceutical Selective PDE Inhibitors Product
Table 94. Teva Pharmaceutical Recent Developments/Updates
Table 95. Torrent Pharmaceuticals Company Information
Table 96. Torrent Pharmaceuticals Description and Business Overview
Table 97. Torrent Pharmaceuticals Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Torrent Pharmaceuticals Selective PDE Inhibitors Product
Table 99. Torrent Pharmaceuticals Recent Developments/Updates
Table 100. Viatris Company Information
Table 101. Viatris Description and Business Overview
Table 102. Viatris Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Viatris Selective PDE Inhibitors Product
Table 104. Viatris Recent Developments/Updates
Table 105. Otsuka Pharmaceutical Company Information
Table 106. Otsuka Pharmaceutical Description and Business Overview
Table 107. Otsuka Pharmaceutical Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Otsuka Pharmaceutical Selective PDE Inhibitors Product
Table 109. Otsuka Pharmaceutical Recent Developments/Updates
Table 110. Sawai Pharmaceutical Company Information
Table 111. Sawai Pharmaceutical Description and Business Overview
Table 112. Sawai Pharmaceutical Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Sawai Pharmaceutical Selective PDE Inhibitors Product
Table 114. Sawai Pharmaceutical Recent Developments/Updates
Table 115. Eurofarma Company Information
Table 116. Eurofarma Description and Business Overview
Table 117. Eurofarma Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Eurofarma Selective PDE Inhibitors Product
Table 119. Eurofarma Recent Developments/Updates
Table 120. Italfarmaco Company Information
Table 121. Italfarmaco Description and Business Overview
Table 122. Italfarmaco Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Italfarmaco Selective PDE Inhibitors Product
Table 124. Italfarmaco Recent Developments/Updates
Table 125. Korea United Pharm Company Information
Table 126. Korea United Pharm Description and Business Overview
Table 127. Korea United Pharm Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Korea United Pharm Selective PDE Inhibitors Product
Table 129. Korea United Pharm Recent Developments/Updates
Table 130. The Menarini Group Company Information
Table 131. The Menarini Group Description and Business Overview
Table 132. The Menarini Group Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. The Menarini Group Selective PDE Inhibitors Product
Table 134. The Menarini Group Recent Developments/Updates
Table 135. Pfizer Company Information
Table 136. Pfizer Description and Business Overview
Table 137. Pfizer Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Pfizer Selective PDE Inhibitors Product
Table 139. Pfizer Recent Developments/Updates
Table 140. Sanofi Company Information
Table 141. Sanofi Description and Business Overview
Table 142. Sanofi Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Sanofi Selective PDE Inhibitors Product
Table 144. Sanofi Recent Developments/Updates
Table 145. Amgen Company Information
Table 146. Amgen Description and Business Overview
Table 147. Amgen Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Amgen Selective PDE Inhibitors Product
Table 149. Amgen Recent Developments/Updates
Table 150. AstraZeneca Company Information
Table 151. AstraZeneca Description and Business Overview
Table 152. AstraZeneca Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. AstraZeneca Selective PDE Inhibitors Product
Table 154. AstraZeneca Recent Developments/Updates
Table 155. Anacor Pharmaceuticals Company Information
Table 156. Anacor Pharmaceuticals Description and Business Overview
Table 157. Anacor Pharmaceuticals Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. Anacor Pharmaceuticals Selective PDE Inhibitors Product
Table 159. Anacor Pharmaceuticals Recent Developments/Updates
Table 160. Glenmark Pharmaceuticals Company Information
Table 161. Glenmark Pharmaceuticals Description and Business Overview
Table 162. Glenmark Pharmaceuticals Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Glenmark Pharmaceuticals Selective PDE Inhibitors Product
Table 164. Glenmark Pharmaceuticals Recent Developments/Updates
Table 165. Bristol Myers Squibb Company Information
Table 166. Bristol Myers Squibb Description and Business Overview
Table 167. Bristol Myers Squibb Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 168. Bristol Myers Squibb Selective PDE Inhibitors Product
Table 169. Bristol Myers Squibb Recent Developments/Updates
Table 170. OriFarm Company Information
Table 171. OriFarm Description and Business Overview
Table 172. OriFarm Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 173. OriFarm Selective PDE Inhibitors Product
Table 174. OriFarm Recent Developments/Updates
Table 175. Kohl Medical Company Information
Table 176. Kohl Medical Description and Business Overview
Table 177. Kohl Medical Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 178. Kohl Medical Selective PDE Inhibitors Product
Table 179. Kohl Medical Recent Developments/Updates
Table 180. Paranova Company Information
Table 181. Paranova Description and Business Overview
Table 182. Paranova Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 183. Paranova Selective PDE Inhibitors Product
Table 184. Paranova Recent Developments/Updates
Table 185. Arcutis Biotherapeutics Company Information
Table 186. Arcutis Biotherapeutics Description and Business Overview
Table 187. Arcutis Biotherapeutics Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 188. Arcutis Biotherapeutics Selective PDE Inhibitors Product
Table 189. Arcutis Biotherapeutics Recent Developments/Updates
Table 190. MSN Laboratories Company Information
Table 191. MSN Laboratories Description and Business Overview
Table 192. MSN Laboratories Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 193. MSN Laboratories Selective PDE Inhibitors Product
Table 194. MSN Laboratories Recent Developments/Updates
Table 195. Hypera Pharma Company Information
Table 196. Hypera Pharma Description and Business Overview
Table 197. Hypera Pharma Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 198. Hypera Pharma Selective PDE Inhibitors Product
Table 199. Hypera Pharma Recent Developments/Updates
Table 200. CSPC Ouyi Pharmaceutical Company Information
Table 201. CSPC Ouyi Pharmaceutical Description and Business Overview
Table 202. CSPC Ouyi Pharmaceutical Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 203. CSPC Ouyi Pharmaceutical Selective PDE Inhibitors Product
Table 204. CSPC Ouyi Pharmaceutical Recent Developments/Updates
Table 205. Qilu Pharmaceutical Company Information
Table 206. Qilu Pharmaceutical Description and Business Overview
Table 207. Qilu Pharmaceutical Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 208. Qilu Pharmaceutical Selective PDE Inhibitors Product
Table 209. Qilu Pharmaceutical Recent Developments/Updates
Table 210. Yabao Pharmaceuticals Company Information
Table 211. Yabao Pharmaceuticals Description and Business Overview
Table 212. Yabao Pharmaceuticals Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 213. Yabao Pharmaceuticals Selective PDE Inhibitors Product
Table 214. Yabao Pharmaceuticals Recent Developments/Updates
Table 215. Lunan Better Pharmaceutical Company Information
Table 216. Lunan Better Pharmaceutical Description and Business Overview
Table 217. Lunan Better Pharmaceutical Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 218. Lunan Better Pharmaceutical Selective PDE Inhibitors Product
Table 219. Lunan Better Pharmaceutical Recent Developments/Updates
Table 220. Yangtze River Pharmaceuticals Company Information
Table 221. Yangtze River Pharmaceuticals Description and Business Overview
Table 222. Yangtze River Pharmaceuticals Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 223. Yangtze River Pharmaceuticals Selective PDE Inhibitors Product
Table 224. Yangtze River Pharmaceuticals Recent Developments/Updates
Table 225. Guangzhou Baiyunshan Company Information
Table 226. Guangzhou Baiyunshan Description and Business Overview
Table 227. Guangzhou Baiyunshan Selective PDE Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 228. Guangzhou Baiyunshan Selective PDE Inhibitors Product
Table 229. Guangzhou Baiyunshan Recent Developments/Updates
Table 230. Key Raw Materials Lists
Table 231. Raw Materials Key Suppliers Lists
Table 232. Selective PDE Inhibitors Distributors List
Table 233. Selective PDE Inhibitors Customers List
Table 234. Selective PDE Inhibitors Market Trends
Table 235. Selective PDE Inhibitors Market Drivers
Table 236. Selective PDE Inhibitors Market Challenges
Table 237. Selective PDE Inhibitors Market Restraints
Table 238. Research Programs/Design for This Report
Table 239. Key Data Information from Secondary Sources
Table 240. Key Data Information from Primary Sources
Table 241. Authors List of This Report


List of Figures
Figure 1. Product Picture of Selective PDE Inhibitors
Figure 2. Global Selective PDE Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Selective PDE Inhibitors Market Share by Type: 2024 & 2031
Figure 4. PDE-3 Product Picture
Figure 5. PDE-4 Product Picture
Figure 6. PDE-5 Product Picture
Figure 7. Global Selective PDE Inhibitors Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Selective PDE Inhibitors Market Share by Application: 2024 & 2031
Figure 9. Heart And Circulatory Conditions
Figure 10. Inflammatory Diseases
Figure 11. Reproductive (Male) Disorders
Figure 12. Respiratory Conditions
Figure 13. Others
Figure 14. Global Selective PDE Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Selective PDE Inhibitors Market Size (2020-2031) & (US$ Million)
Figure 16. Global Selective PDE Inhibitors Sales (2020-2031) & (K Units)
Figure 17. Global Selective PDE Inhibitors Average Price (US$/Unit) & (2020-2031)
Figure 18. Selective PDE Inhibitors Report Years Considered
Figure 19. Selective PDE Inhibitors Sales Share by Manufacturers in 2024
Figure 20. Global Selective PDE Inhibitors Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Selective PDE Inhibitors Players: Market Share by Revenue in Selective PDE Inhibitors in 2024
Figure 22. Selective PDE Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Selective PDE Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Selective PDE Inhibitors Sales Market Share by Country (2020-2031)
Figure 25. North America Selective PDE Inhibitors Revenue Market Share by Country (2020-2031)
Figure 26. United States Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Selective PDE Inhibitors Sales Market Share by Country (2020-2031)
Figure 29. Europe Selective PDE Inhibitors Revenue Market Share by Country (2020-2031)
Figure 30. Germany Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Selective PDE Inhibitors Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Selective PDE Inhibitors Revenue Market Share by Region (2020-2031)
Figure 37. China Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. China Taiwan Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Selective PDE Inhibitors Sales Market Share by Country (2020-2031)
Figure 45. Latin America Selective PDE Inhibitors Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Colombia Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Middle East and Africa Selective PDE Inhibitors Sales Market Share by Country (2020-2031)
Figure 51. Middle East and Africa Selective PDE Inhibitors Revenue Market Share by Country (2020-2031)
Figure 52. Turkey Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Saudi Arabia Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. UAE Selective PDE Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Global Sales Market Share of Selective PDE Inhibitors by Type (2020-2031)
Figure 56. Global Revenue Market Share of Selective PDE Inhibitors by Type (2020-2031)
Figure 57. Global Selective PDE Inhibitors Price (US$/Unit) by Type (2020-2031)
Figure 58. Global Sales Market Share of Selective PDE Inhibitors by Application (2020-2031)
Figure 59. Global Revenue Market Share of Selective PDE Inhibitors by Application (2020-2031)
Figure 60. Global Selective PDE Inhibitors Price (US$/Unit) by Application (2020-2031)
Figure 61. Selective PDE Inhibitors Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit